about
Monoclonal antibodies targeting CD38 in hematological malignancies and beyondCrystal structure of a neutralizing human IGG against HIV-1: a template for vaccine designStatins impair antitumor effects of rituximab by inducing conformational changes of CD20Opening the door to innovationHexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationComplement is activated by IgG hexamers assembled at the cell surface.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsBinding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Neutralizing human Fab fragments against measles virus recovered by phage displayDetection of antibodies against the four subtypes of ebola virus in sera from any species using a novel antibody-phage indicator assay.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging.Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent ModelsNeutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.The antiviral activity of antibodies in vitro and in vivo.HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe.The INNs and outs of antibody nonproprietary names.Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expressionA Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomaInhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralizationEfficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CAProduction of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design
P50
Q26766718-82503D1E-DCE8-4B51-BAA5-F278F4FDE3BAQ27634018-8905D70D-D5C1-4E3A-9996-088B54DE0C26Q28472420-4C3C7EDB-7186-47BC-9FE5-1E7F0CAA8CDBQ28655591-82A66A9E-91D8-4D97-A8C9-E869A712A095Q30252215-FBD45128-E422-463F-8DE5-907634CE9F6EQ30276243-F8F7F785-BE6F-4305-8C46-A8E72D7BF5D2Q30277882-6C255477-7164-4A8A-BECF-E2F039790F6EQ30303054-E819C831-1912-4EC0-B513-45EFACE84A8FQ30360964-A5928B4C-35CA-440F-8494-A3D4161FB8AFQ30409381-24E1C71D-F46F-4D02-A4D9-12C0DD72A490Q30421637-8A0B7205-A7E5-4851-8488-69BD5B411DD0Q30448599-D313B85A-B156-415D-9D8B-83160D80C226Q30454102-76ECBE23-1996-45E3-ABC8-70176DAEA40EQ30701127-6704BA3C-9808-4ED6-9165-2B8199A07099Q30706865-E9080D57-4055-477D-A6D0-866D8AE84C4FQ30804794-67019A4C-29ED-4063-B900-935CA889F1D0Q31016954-36552558-17BE-45E3-8110-4BF6814D37B5Q31032269-5C46E52C-F8E8-489B-9352-7622357F3191Q31112631-0F75315C-89A5-421F-867E-8CEEDF8DD894Q31143293-170A9902-BC99-4E57-B9CA-50B62374B6F4Q33515169-B59B5CE7-2508-4AC1-924D-22A0808E6BC5Q33681420-20F8C015-A83A-41BF-966E-6AE61B19147FQ33740334-CB9206EA-F0F0-4061-B498-853B7C10EE28Q33860721-B6A238B6-5BCE-4F8D-8F8E-41BCEAB8B9BBQ33870167-9721262E-4456-4D8F-BF33-24A34B527A61Q33870236-39DD2E54-2D71-4125-A98A-62751938A692Q34156748-C9E4AE2B-529A-45AF-AA51-7D77BEC8EB2DQ34212487-3DCD574C-0889-44E4-A6FA-071FD151C76FQ34623592-C3B11F8B-05E6-4E0D-93AF-DA871C0DD550Q35827605-6DF44868-0F47-4DCF-BD6B-1CF7029A7F52Q35881712-19073ECC-F09B-429C-9DF3-16CC377EAE04Q35882193-99F7C790-2A75-46DD-9935-0E697356093FQ35886917-19D08A3E-0013-477B-92F8-FACFEF82E8B4Q36213431-79266E0C-58FE-461E-97A3-DDA7B032A027Q36380741-9053A84D-90EA-47E8-9895-76C11898576FQ36729822-BE0A8BDA-F687-4CCC-A6E4-47D1254BE512Q37025857-25FF7CB7-9137-4E55-9CF8-CCA5DFB3A1B1Q37397677-BCF62B37-0FAE-478F-A8C8-CDCAB8BFB084Q37496596-CC77C64A-E670-46B1-9831-79EBB2101658Q37698925-2A8A9C46-8D8C-45B6-A210-0743E7F94BC5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Paul Whi Parren
@ast
Paul Whi Parren
@en
Paul Whi Parren
@es
Paul Whi Parren
@sl
type
label
Paul Whi Parren
@ast
Paul Whi Parren
@en
Paul Whi Parren
@es
Paul Whi Parren
@sl
prefLabel
Paul Whi Parren
@ast
Paul Whi Parren
@en
Paul Whi Parren
@es
Paul Whi Parren
@sl
P1006
P214
P1006
P106
P1153
7004044140
P2038
Paul_Parren
P21
P214
P2798
P31
P496
0000-0002-4365-3859
P735
P7859
viaf-287928302